<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>15(11)</volume><submitter>Akbar S</submitter><pubmed_abstract>It is evident that inflammation and metabolic syndrome instigated by diabetes mellitus can precipitate diabetes-induced neuropathy (DIN) and pain. In order to find an effective therapeutic method for diabetes-related problems, a multi-target-directed ligand model was used. 6-Hydroxyflavanone (6-HF) carrying anti-inflammatory and anti-neuropathic pain potential due to its quadruplicate mechanisms, targeting cyclooxygenase-2 (COX-2), 5-lipoxygenase (5-LOX), and opioid and GABA-A receptors was investigated. The anti-inflammatory potential of the test drug was confirmed utilizing in silico, in vitro, and in vivo tests. A molecular simulation approach was utilized to observe the interaction of 6-HF with the inflammatory enzyme COX-2 as well as opioid and GABA-A receptors. The same was confirmed</pubmed_abstract><journal>Nutrients</journal><pagination>2552</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10255489</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Targeting Anti-Inflammatory Pathways to Treat Diabetes-Induced Neuropathy by 6-Hydroxyflavanone.</pubmed_title><pmcid>PMC10255489</pmcid><pubmed_authors>Ahmad A</pubmed_authors><pubmed_authors>Akbar S</pubmed_authors><pubmed_authors>Akbar A</pubmed_authors><pubmed_authors>Habib F</pubmed_authors><pubmed_authors>Subhan F</pubmed_authors><pubmed_authors>Salman S</pubmed_authors><pubmed_authors>Shahbaz N</pubmed_authors><pubmed_authors>Wadood A</pubmed_authors></additional><is_claimable>false</is_claimable><name>Targeting Anti-Inflammatory Pathways to Treat Diabetes-Induced Neuropathy by 6-Hydroxyflavanone.</name><description>It is evident that inflammation and metabolic syndrome instigated by diabetes mellitus can precipitate diabetes-induced neuropathy (DIN) and pain. In order to find an effective therapeutic method for diabetes-related problems, a multi-target-directed ligand model was used. 6-Hydroxyflavanone (6-HF) carrying anti-inflammatory and anti-neuropathic pain potential due to its quadruplicate mechanisms, targeting cyclooxygenase-2 (COX-2), 5-lipoxygenase (5-LOX), and opioid and GABA-A receptors was investigated. The anti-inflammatory potential of the test drug was confirmed utilizing in silico, in vitro, and in vivo tests. A molecular simulation approach was utilized to observe the interaction of 6-HF with the inflammatory enzyme COX-2 as well as opioid and GABA-A receptors. The same was confirmed</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 May</publication><modification>2025-04-04T10:22:00.156Z</modification><creation>2025-02-19T02:38:16.995Z</creation></dates><accession>S-EPMC10255489</accession><cross_references><pubmed>37299516</pubmed><doi>10.3390/nu15112552</doi></cross_references></HashMap>